Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00649428 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles
A Phase 3 study of Bilateral Nasolabial Fold Wrinkles, sponsored by Castle Creek Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 203
- Enrollment target
- 7
- Study locations
NCT00649428 is a Phase 3 study of Bilateral Nasolabial Fold Wrinkles that has completed, run by Castle Creek Biosciences. The registered enrollment target is 203 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT00649428, a Phase 3 study of Bilateral Nasolabial Fold Wrinkles, has completed, sponsored by Castle Creek Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 203 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM compared with placebo when administered to bilateral nasolabial fold wrinkles.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Autologous Human Fibroblast (azficel-T)
Study Locations (7)
North Carolina
- Aesthetic Solutions - Chapel Hill
- Dermatology, Laser & Vein Specialists of the Carolinas - Charlotte
Alabama
- Total Skin & Beauty Dermatology Center, PC - Birmingham
California
- Silverburg Surgical & Medical Group - Newport Beach
Florida
- Dermatology Research Institute, LLC - Coral Gables
Illinois
- River North Dermatology and Dermatologic Surgery - Naperville
Texas
- Center for Skin Research - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00649428
The ClinicalTrials.gov registry entry for NCT00649428 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Castle Creek Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bilateral Nasolabial Fold Wrinkles appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00649428 reports 7 study locations spanning 6 distinct geographic areas - top geographies include North Carolina, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00649428 about?
NCT00649428 is a clinical study titled "Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles". The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM compared with placebo when administered to bilateral nasolabial fold wrinkles.
What is the current status of trial NCT00649428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 203 participants. The study started on 2006-10. Estimated completion is 2009-05.
What conditions does trial NCT00649428 study?
This clinical trial studies the following conditions: Bilateral Nasolabial Fold Wrinkles.
What interventions are being tested in trial NCT00649428?
The interventions under investigation include: Placebo (BIOLOGICAL), Autologous Human Fibroblast (azficel-T) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00649428?
This trial is sponsored by Castle Creek Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00649428 being conducted?
This trial has 7 study locations across Alabama, California, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.